MedPacto "Three Research Results Selected as Presentation Topics at AACR USA"

[Asia Economy Reporter Hyunseok Yoo] MedPacto, a biomarker-based innovative drug development company, announced on the 3rd that all three research results submitted to the American Association for Cancer Research (AACR) annual meeting were selected as official presentation topics.

AACR is a global annual academic conference with participation from over 120 countries worldwide, serving as a platform to share basic and clinical cancer research. The abstracts of the research results submitted by MedPacto are scheduled to be released on March 10.

The selected presentation topics include ▲ BAG2 mechanism research results ▲ DRAK1 mechanism research results ▲ preclinical animal experiment results of the combination therapy of Baektoceptip and Onivide for pancreatic cancer. Among these, the abstracts to watch are the research results on BAG2 and DRAK1, which are follow-up pipelines of Baektoceptip.

BAG2 is a protein whose mechanism of action in triple-negative breast cancer (TNBC) was first identified globally by CEO Sungjin Kim. Through preclinical studies, it was revealed that BAG2 regulates the function of cathepsin B, a key factor in carcinogenesis, promoting tumor formation and lung metastasis.

Furthermore, the research team confirmed that BAG2 was detected at high levels not only in triple-negative breast cancer but also in other cancers such as ovarian cancer. MedPacto is currently accelerating product commercialization by collaborating with the US global life sciences company Thermo Fisher Scientific to develop a diagnostic kit capable of predicting breast cancer metastasis and recurrence based on the BAG2 candidate substance.

Similarly, DRAK1 is a candidate substance whose mechanism of action in cervical cancer (HPV) was first identified by CEO Sungjin Kim. The research team confirmed that DRAK1 binds to and induces degradation of the TRAF6 protein, regulating cancer cell metastasis. Based on this, they concluded that increasing DRAK1 gene expression can control cancer growth and lung metastasis.

Currently, DRAK1 is being developed as an activation-inhibiting compound, and its anticancer effects will be confirmed through preclinical trials targeting hard-to-treat cancers such as ovarian cancer and brain cancer, which have limited treatment options.

MedPacto views the mechanism research results of these two candidate substances as a foundation for discovering biomarkers that can predict recurrence and metastasis of hard-to-treat cancers such as triple-negative breast cancer, cervical cancer, and ovarian cancer in the future.

In addition, MedPacto plans to present preclinical results of the combination therapy of Baektoceptip and Onivide as a treatment for pancreatic cancer. These research outcomes are also expected to serve as supporting data for applying for Orphan Drug Designation (ODD) with the US Food and Drug Administration (FDA).

A MedPacto official stated, “These research results will serve as an opportunity to validate the mechanism of action of Baektoceptip’s expanded indications as well as follow-up pipelines at a global conference,” adding, “Meaningful achievements in new drug development will be sequentially disclosed this year as well, just like last year.”

This content was produced with the assistance of AI translation services.